Navigation Links
Bexion Pharmaceuticals Continues to Gain Support from National Cancer Institute (NCI)
Date:10/8/2010

COVINGTON, Ky., Oct. 8 /PRNewswire/ -- Bexion Pharmaceuticals announced today that it has been awarded a $1.5M Phase II Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI). The grant entitled "SapC-DOPS Nanovesicles for Treating Glioblastoma Multiforme" was awarded September 28, 2010 and covers a two year period.  This announcement from NCI follows their September 20, 2010 announcement selecting Bexion for a notable research collaboration with NCI's Nanotechnology Characterization Laboratory (NCL), part of a major program, the Alliance for Nanotechnology in Cancer, to advance the medical applications of nanotechnology.

Bexion's proprietary technology is based on Saposin C- dioleoylphosphatidylserine (dubbed "SapC-DOPS") and is a first-in-class nanovesicle therapeutic for the treatment of glioblastomas (GBM), pancreatic cancers, and other solid tumors.  These nanovesicles have preferential affinity for phosphatidylserine-enriched membrane patches which appear to be common in many types of tumor cells and tumor neovasculature.  Bexion's initial studies of SapC-DOPS nanovesicles have shown that they induce apoptosis in cancer cell lines and also demonstrated in vivo efficacy in multiple tumor models.

The intent of this Phase II SBIR grant is to identify and select optimized SapC-DOPS formulations and treatment methods for glioblastoma multiforme, suitable for advancing Bexion's drug toward planned human testing. Upon the completion of these studies, Bexion expects to have compelling evidence to progress into clinical development.

"This Phase II award will expedite our goal to develop a new molecular entity with a novel mechanism of action for targeting and eliminating glioblastoma multiforme (GBM, high grade glioma), a deadly and invasive brain tumor with no effective treatment," stated Dr. Ray Takigiku, Bexion's co-founder and CEO. "Of the 12,000 patients expected to be diagnosed with GBM this year, most will succumb within the first year. Clearly, there is an urgent demand for an efficacious anti-glioma drug."

This SBIR Phase II award is the fourth grant won by Bexion from the NCI. Past awards include Phase I grants for treating Metastatic Prostate, Pancreatic and Glioblastoma Multiforme.

About Bexion Pharmaceuticals:

Bexion Pharmaceuticals is focused on the development and commercialization of innovative cures for cancer.  Initial products are based on a proprietary platform technology licensed from Cincinnati Children's Hospital Medical Center.  The technology has demonstrated potential for development as therapeutics, diagnostic and surgical imaging reagents, and as carriers for other pharmaceutical agents, such as oligonucleotides.  For more information, visit www.bexionpharma.com.


'/>"/>
SOURCE Bexion Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Onyx Pharmaceuticals Provides Status Update on Carfilzomib
2. Onyx Pharmaceuticals Announces Teleconference to Provide Status Update on Carfilzomib
3. Star Scientific Comments on Roskamp Institutes Plans to Conduct Human Alzheimers Clinical Trials Using a Compound (RCP-006) Developed by Rock Creek Pharmaceuticals, Inc.
4. VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis
5. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
6. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
7. ISTA Pharmaceuticals Reports Positive Preliminary Results from its Phase 1/2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
8. MAP Pharmaceuticals Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
9. Savient Pharmaceuticals Announces Dismissal of Class Action Lawsuit
10. Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results
11. Transcept Pharmaceuticals to Present at BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... -- Lannett Company, Inc. (NYSE: LCI ) today announced that ... for Success Healthcare Conference on December 14, 2016 at 9:20 a.m. ... City . In addition, the company will host ... th Annual Boston Healthcare Conference taking place on December 13, ... ...
(Date:12/6/2016)... Mass. , Dec. 6, 2016  Alopexx Oncology, ... DI-Leu16-IL2, a recombinant antibody fusion protein (immunocytokine) composed of ... recognizes the same target on B cells as Rituxan ... cytokine components but is also involved in tumor targeting, ... anti-cancer vaccine effect. The results of the study (abstract ...
(Date:12/6/2016)... , Dec. 6, 2016 Diabetes & Obesity ... diabetes and obesity disease cluster is currently dominated by ... type 2 diabetes mellitus (T2DM), and the majority of ... of products, is attributable to these indications. While products ... market presence, there are a large number of these ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... , ... “The Road To Restoration”: an informative and enlightening book for ... week showing of hands. “The Road To Restoration” is the creation of published author, ... the brass ring that you could reach out for, and grab, on the old ...
(Date:12/7/2016)... ... ... “Walking With God: Inspirational Lessons from My Life's Journey”: a sometimes serious, ... God's direction in their lives. “Walking With God: Inspirational Lessons from My Life's Journey” ... , Sanford says, “I enjoy sharing the true stories in my book ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... Angioma Alliance ( ... cavernous angiomas, was awarded a grant from the Julian Grace Foundation to increase ... has more people with cavernous angioma than anywhere in the world. Most share ...
(Date:12/7/2016)... ... 07, 2016 , ... Dr. Greg Leyer, the Chief Scientific ... Washington DC workshop on November 2nd. The conference was an opportunity for both ... supplement regulations. , Dr. Leyer spoke about two main topics at the ...
(Date:12/7/2016)... ... 2016 , ... "Hacking into my medical record wouldn’t be hard for my ... begins "Margaret in Berlin," Book Twelve in the Margaret of Greenwich ® Young ... These novels narrate the lives of a poor teenager and her wealthy friends in ...
Breaking Medicine News(10 mins):